^(18)F-FDG PET-CT在嵌合抗原受体T细胞治疗B细胞淋巴瘤中的应用研究进展  

Application progress of ^(18)F-FDG PET-CT in chimeric antigen receptor T-cell therapy for B-cell lymphoma

作　　者：齐建昌 闫宇涛 张烁 Qi Jianchang;Yan Yutao;Zhang Shuo(Department of Radiology,No.988 Hospital of Joint Logistic Support Force,Zhengzhou 450007,China)

机构地区：[1]联勤保障部队第九八八医院放射诊断科,郑州450007

出　　处：《白血病．淋巴瘤》2024年第6期377-380,共4页Journal of Leukemia & Lymphoma

摘　　要：近年来, 嵌合抗原受体T细胞(CAR-T)在恶性血液系统肿瘤的治疗中体现了一定的价值, 尤其是对于复发难治B细胞淋巴瘤患者。目前, ^(18)F-FDG PET-CT已经证明在淋巴瘤的诊疗中占有重要的临床价值。应用^(18)F-FDG PET-CT评估接受CAR-T治疗B细胞淋巴瘤的研究相对较少, 但也取得了不错的结果。文章就^(18)F-FDG PET-CT在CAR-T治疗B细胞淋巴瘤中的应用研究进展进行综述。In recent years,chimeric antigen receptor T-cell(CAR-T)therapy has shown a certain value in the treatment of malignant hematological tumors,especially for patients with relapsed/refractory B-cell lymphoma.Currently,^(18)F-FDG PET-CT has proved its great clinical values in the diagnosis and treatment of lymphoma.There are relatively few studies using ^(18)F-FDG PET-CT to evaluate B-cell lymphoma treated by CAR-T therapy,but some good results have also been achieved.This paper reviews the current research progress of ^(18)F-FDG PET-CT in CAR-T therapy for B-cell lymphoma.

关 键 词：^(18)F-FDG PET-CT 嵌合抗原受体T细胞 B细胞淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]